Clinical efficacy of hepatic artery chemoembolization combined with systemic treatment in the treatment of recurrent hepatocellular carcinoma with abdominal lymph node metastasis
10.3760/cma.j.cn115610-20220904-00489
- VernacularTitle:肝动脉化疗栓塞联合系统治疗肝细胞癌术后复发及腹腔淋巴结转移的临床疗效
- Author:
Liang XU
1
;
Guang CAO
;
Xiaodong WANG
;
Xu ZHU
;
Hongwei WANG
;
Xianggao ZHU
;
Hui CHEN
;
Peng LIU
;
Haifeng XU
;
Jianhai GUO
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所介入治疗科 恶性肿瘤发病机制及转化研究教育部重点实验室，北京 100142
- Keywords:
Liver neoplasms;
Targeted therapy;
Hepatic artery chemoembolization;
Recurrence;
Lymph node metastasis
- From:
Chinese Journal of Digestive Surgery
2022;21(S1):1-4
- CountryChina
- Language:Chinese
-
Abstract:
In China, patients with hepatocellular carcinoma (HCC) are usually with late stage and long medical history when diagnosed, resulting in a lower 5-year survival rate. For advanced HCC, guidelines from different countries have different indications for local treatment. The applica-tion of hepatic artery chemoembolization has brought new treatment opportunities to patients with advanced HCC. Due to tumor heterogeneity, the response to immunotherapy is different in patients with intrahepatic recurrent lesions and extrahepatic metastatic lesions of primary hepatic carcinoma. Therefore, hepatic artery chemoembolization combined with systemic treatment is beneficial to prolong the survival of patients. The authors introduce the clinical experience of a patient with recurrent advanced HCC combined with abdominal lymph node metastasis who was treated with hepatic artery chemoembolization combined with atezolizumab plus bevacizumab. The results show that tumor is controlled in a short period with a good clinical effect.
